Cardiology

No clear benefit for rivaroxaban after hospital discharge

(HealthDay)—Rivaroxaban does not lower risk of symptomatic venous thromboembolism and related death in medical patients after hospital discharge, compared to placebo, according to a study published in the Sept. 20 issue ...

Cardiology

Drug dosage recommendation model

NUS pharmaceutical scientists have developed a prediction model to guide dosage adjustments of rivaroxaban, an oral anticoagulant (blood thinner), in renal-impaired patients taking amiodarone. This is to reduce the risk of ...

Neuroscience

Warfarin, rivaroxaban similarly safe, effective

(HealthDay)—For cases of mild atrial fibrillation (AF)-related acute ischemic stroke, rivaroxaban and warfarin are similarly safe and effective at preventing recurrent stroke, according to a study published online Sept. ...

Cardiology

Rivaroxaban OK for stroke prevention in cancer patients

(HealthDay)—The safety and efficacy of rivaroxaban treatment for nonvalvular atrial fibrillation (AF) in patients with active cancer is similar to the general population, according to a study published in the July 15 issue ...

Diseases, Conditions, Syndromes

Lower risk of gastrointestinal bleeding for apixaban

(HealthDay)—For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, ...

Cardiology

Rivaroxaban reduces VTE recurrence compared with aspirin

In patients at elevated risk for a recurrence of potentially life-threatening blood clots, a low dose of the oral blood-thinning medication rivaroxaban reduced recurrences more than three-fold compared with aspirin, with ...

page 2 from 4